A, M., K, L., C, C., J, P., A, H., J, R., & M, P. (2026). Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk-proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024. British journal of clinical pharmacology, 92(3), 822. https://doi.org/10.1002/bcp.70308
Chicago Style (17th ed.) CitationA, Manfrin, Lee K, Cacou C, Pound J, Harnden A, Raine J, and Pirmohamed M. "Evaluation of the Medicines and Healthcare Products Regulatory Agency's Introduction of a Risk-proportionate Approach for Clinical Trials: An Analysis of 4617 Applications Assessed Between September 2023 and August 2024." British Journal of Clinical Pharmacology 92, no. 3 (2026): 822. https://doi.org/10.1002/bcp.70308.
MLA (9th ed.) CitationA, Manfrin, et al. "Evaluation of the Medicines and Healthcare Products Regulatory Agency's Introduction of a Risk-proportionate Approach for Clinical Trials: An Analysis of 4617 Applications Assessed Between September 2023 and August 2024." British Journal of Clinical Pharmacology, vol. 92, no. 3, 2026, p. 822, https://doi.org/10.1002/bcp.70308.
